Marinus Pharmaceuticals — Investor Presentation (October 2019)
35 slides from Marinus Pharmaceuticals's investor presentation, Oct 21, 2019
Slide 1: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private
Slide 2: Strategic Overview
Strategic Overview Ganaxolone: a positive allosteric GABAA modulator with a well-defined MOA designed to treat patients suffering from epilepsy and neuropsychiatric disorders 3 Acute Delivery Chronic Administration ganaxolone Extensive safety record in more than 1,600 subjects both pediatric and adu
Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABAA Receptors
Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABAA Receptors GNX is a synthetic analog of allopregnanolone GNX is designed to modulate both synaptic and extrasynaptic GABAA receptors to calm over-excited neurons 4
Slide 4: Ganaxolone Development Pipeline
GANAXOLONE PHASE 1 PHASE 2 PHASE 3 MILESTONES Orphan Refractory Seizure Programs Data Q3 2020 Data 2021 Depressive Disorders* Ganaxolone Development Pipeline Severe PPD TRD Refractory Status Epilepticus 5 PCDH19-Related Epilepsy CDKL5 Deficiency Disorder *Pending regulatory interactions and funding
Slide 5: Orphan Refractory Epilepsy Indications
Orphan Refractory Epilepsy Indications
Slide 6: Refractory Status Epilepticus (RSE)
Cause Brain trauma, tumor, stroke, infection, among others Symptoms Seizure lasting >5 minutes or several seizures within 5 minutes with no recovery between seizures Prevalence ~45,000 patients fail 1st line treatment (US)1, 2 Orphan Drug Designation Treatments Few treatments available Benzodiazepin
Slide 7: Goals of a New Treatment for RSE
Goals of a new treatment for RSE Prevent patient progression towards escalation of treatment (IV anesthetics) Rapid cessation of SE Maintenance of seizure control over study period Goals of a New Therapy for the Treatment of RSE Benzodiazepine Administered Medically induced Coma Established Status E
Slide 8: Status Epilepticus - U.S. Hospital Incidence
Status Epilepticus - U.S. Hospital Incidence 75K Total SE Patients Annually in U.S. 23 unique ICD-10 codes with some reference to SE Refractory SE patient volumes range from 12.5K to 37.5K Minimum = patients coded as “intractable” in ICD-10 (understated) Maximum = 30%-50% of patients cited as refrac
Slide 9: Rationale for IV Ganaxolone for the Treatment of RSE
Ganaxolone has demonstrated a broad range of anticonvulsant and psychotherapeutic responses Rationale for IV Ganaxolone for the Treatment of RSE Benzodiazepines are effective in treating acute seizures but not RSE Benzodiazepines are positive allosteric modulators of the synaptic (gamma subunit) GAB
Slide 10: Phase 2 RSE Trial Design
Treatment Period Loading Dose Maintenance Taper Phase 2 RSE Trial Design Diagnosis of convulsive or non-convulsive SE Failed at least one 2nd line IV AED but not progressed to 3rd line IV anesthetics Bolus plus continuous infusion 2-4 day infusion 18 hour taper Screening Post-treatment Follow-up 24
Slide 11: Phase 2 RSE Trial – Efficacy of IV Ganaxolone
Phase 2 RSE Trial – Efficacy of IV Ganaxolone 12 Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free at 24 hours from infusion initiation No escalation to additional IV AEDs or IV anesthetics for status relapse at any time through the follow
Slide 12: Target Dose Provided Shorter ICU Time and Greater CGI-I Improvement
Target Dose Provided Shorter ICU Time and Greater Improvements in CGI-I at Follow-up 13 CGI-I at Final Follow-up Visit (Target Dose) 3: Minimally Improved n=1 2: Much Improved n=1 1: Very Much Improved n=5 *1 patient in Target Dose died due to perforated bowel (not related)
Slide 13: PK Data Supports Target Dosing
PK Data Supports Target Dosing 14 Modeled PK curves Cohort Dose of GNX/day N Low 500mg/day 5 Medium 650mg/day 4 Target 713mg/day 8 Clinical data presented at NCS 2019 0 3 6 9 0 200 400 600 800 1,000 Time (hrs) G N X P l a s m a C o n c e n t r a t i o n ( n g / m L ) Low (model) Low Dose Patient Rec
Slide 14: Phase 2 RSE Trial - IV Ganaxolone Safety Summary
2 related in 2 patients 2 severe sedation 13 related in 7 patients 6 mild (2 hypotension, 2 somnolence, 1 urinary retention, 1 hypercarbia) 5 moderate (4 somnolence, 1 hypercarbia) 2 severe (2 sedation) Phase 2 RSE Trial - IV Ganaxolone Safety Summary 15 10 SAEs in 6 patients (also included in AEs)
Slide 15: CDKL5 Deficiency Disorder (CDD)
Cause Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome Symptoms Early-onset, treatment refractory seizures, & severe neuro-developmental delay Most can’t walk, talk or care for themselves Suffer from scoliosis, visual impairment, gastrointestinal difficulties
Slide 16: CDD - Phase 2 Trial Design
Trial Details Baseline Characteristics Endpoints 2 sites in US; 1 site in Italy Median number seizures - 343 (range 101 to 584) Primary: % change in seizure frequency per 28 days relative to baseline 6 females, 1 male – ages 2-16 Confirmed CDKL5 mutation, stable background treatment, >4 seizures per
Slide 17: Efficacy & Safety in Phase 2 Trial in CDD
Very much improved no change Very much worse Efficacy & Safety in Phase 2 Trial in CDD Data presented at AES 2018 18 Patients experienced a median ‘minimally improved’ rating on CGI-I scale (Clinician rated) correlated with % change in seizure frequency GNX was generally safe and well-tolerated (no
Slide 18: Durable Responses Seen in CDD Phase 2 Extension
Durable Responses Seen out to 18 Months in CDD Phase 2 Extension 4 of 7 patients entered the extension period Ganaxolone demonstrated preliminary evidence of sustained, long-term (out to 18 months) efficacy in a small cohort of CDD patients Efficacy of existing AEDs and the ketogenic diet in patient
Slide 19: Global Phase 3 Pivotal Study Design
Global Phase 3 Pivotal Study Design 20 Ganaxolone (600 mg, 3x day maximum) Baseline 6 weeks R 1:1 Historical Control 8 weeks Double-Blind Phase Open-Label Phase Maintenance 13 weeks Titration 4 weeks Titration 4 weeks Open-Label Phase n=100 Ganaxolone (600 mg, 3x day maximum) Placebo Trial Details E
Slide 20: PCDH19-Related Epilepsy
Cause Inherited mutation of protocadherin 19 (PCDH19) gene. Located on X chromosome Symptoms Early-onset seizures, cognitive and sensory impairment, & psychiatric and behavioral disorders. Seizures last from days to weeks; sensitive to fever Prevalence Affects ~10-12K children US and EU5 Predominant
Slide 21: Significant Seizure Reduction in PCDH19 Phase 2 Trial
Significant Seizure Reduction in PCDH19 Phase 2 Trial in Patients with Low Allo Levels 25% decrease in median seizure frequency reported in Phase 2 (n=11) Stratification of patients by baseline plasma Allo levels identifies a subpopulation with improved efficacy on GNX When comparing seizure frequen
Slide 22: Biomarker Stratified Phase 3 Pivotal Study in PCDH19
Biomarker Stratified Phase 3 Pivotal Study in PCDH19 23 R 1:1 PCDH19 (all-patients) n~ 70 Biomarker + n = 50 Low Allo-S Primary efficacy analyses will be conducted using this cohort Biomarker - n~ 20 High Allo-S R 1:1 Ganaxolone Up to 600 mg 3x/day Placebo Ganaxolone Up to 600 mg 3x/day Placebo Gana
Slide 23: Broad Potential for Biomarker Driven Strategy in Rare Genetic Epilepsies
Broad Potential for Biomarker Driven Strategy in Rare Genetic Epilepsies Depending on results, additional biomarker trials for rare genetic epilepsies may be started Based on the strength of these data, retrospective Allo-S biomarker analyses are being conducted to identify other rare genetic epilep
Slide 24: Allo-S as Potential Biomarker Across Various Genetic Epilepsies
Allo-S as Potential Biomarker Across Various Genetic Epilepsies 25
Slide 25: PPD Market Segmentation and Value
Total Annual U.S. PPD Prevalence* ~550K Patients (100%) PPD Market Segmentation and Value *PPD prevalence estimated at ~13% of total 2018 live births of 4.1MM – RBC Analyst report 10/18/18 27 Mild PPD Severe PPD 10% - 20% of moderate and severe PPD patients require hospitalization Moderate PPD
Slide 26: Systematic Evaluation of Ganaxolone Dosing Regimens for PPD
Systematic Evaluation of Ganaxolone Dosing Regimens for PPD 28 Part 1 Part 2 48-hour IV + 12-hour taper 6-hour IV + 900mg oral + Oral 675mg Oral 675mg/BID for 2 days then 1125 mg for 26 days Early onset of action Good safety Attractive efficacy Low Dose High Dose
Slide 27: IV Ganaxolone: Competitive Profile for Onset of Action, Safety and Ease
IV Ganaxolone: Competitive Profile for Onset of Action, Safety/Tolerability and Ease of Administration 29 PART 1 48 hour plus 12 hour taper IV provided rapid onset of action that was durable through one month after stopping treatment Dose response observed Multiple efficacy scales (clinician- and pa
Slide 28: HAM-D17 Response and Remission Rates - ITT Population
HAM-D17 Response and Remission Rates - ITT Population 30 Remission: HAM-D17 > 7 points Response: HAM-D17 decrease > 50% HAM-D17 Response Rates HAM-D17 Remission Rates
Slide 29: Amaryllis – Oral Dosing Showed Decrease in HAM-D17
Amaryllis – Oral Dosing Showed Encouraging Decrease in HAM-D17 in High Dose Cohort 31 HAM-D17 Reduction Day 2 Day 15 Day 29 Low dose (675mg) 0.8 9.8 12.2 High dose (1125mg) 2.7 9.3 14.5
Slide 30: Favorable Safety Profile Across Regimens
Favorable Safety Profile Across Regimens 01 Ganaxolone appeared safe and well-tolerated 02 Most common reported AEs were dizziness and sedation 03 No SAEs, no discontinuations due to a TRAE 04 Consistent with prior studies, no reports of syncope or loss of consciousness 32
Slide 31: Multiple Milestones
Multiple Milestones 33 FDA EOP2 meeting for RSE 1Q 2020 CDD Phase 3 data Q3 2020 Initiate P3 in RSE Mid 2020
Slide 32: Patent Portfolio: Multiple Layers Of Protection
Orphan Drug protection (SE, CDD, PCDH19) 7 years US / 10 years EU IV formulations and methods of use applications filed patent life 2036 expected IV formulations containing exclusively in-licensed proprietary captisol product patent life 2033 Nanoparticle formulation patents issued in the US (e.g.,
Slide 33: Ganaxolone’s Potential to Offer Continuity of Care
Ganaxolone’s Potential to Offer Continuity of Care Status Epilepticus, Pediatric Seizure Disorders, Postpartum Depression Attractive orphan indications & large market indications Significant unmet medical need – no or few treatment options Targeted patient populations – understood dysfunctional GABA
Slide 34: Ganaxolone’s Potential to Offer Continuity of Care
Ganaxolone’s Potential to Offer Continuity of Care Status Epilepticus, Pediatric Seizure Disorders, Postpartum Depression Attractive orphan indications & large market indications. t 7 ‘Significant unmet medical need — no or few treatment options | | Targeted patient populations — understood dysfunct
Slide 35: Thank You
Thank You
Marinus Pharmaceuticals — Investor Presentation (October 2019) on 6ix